Rocket Pharmaceuticals
RCKT
60 hedge funds and large institutions have $218M invested in Rocket Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 8 closing their positions.
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
24% more capital invested
Capital invested by funds: $175M → $218M (+$42.7M)
13% more funds holding
Funds holding: 53 → 60 (+7)
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.38M |
| 2 |
SAM
Senzar Asset Management
New York
|
+$3.37M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
+$3.18M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$799K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$753K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCP
Rho Capital Partners
New York
|
-$2.65M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.45M |
| 3 |
KCM
Kingdon Capital Management
New York
|
-$1.08M |
| 4 |
CCI
Columbus Circle Investors
|
-$798K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$619K |
RCKT Hedge Fund Activity: Q4 2015 in Review
60 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2015, worth a combined $218M — up 24% from $175M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RCKT positions and 8 closed out — a net gain of 8 holders — while 16 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $3.38M. The largest seller was Rho Capital Partners, cutting an estimated $2.65M.
- 60 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2015, up from 53 in Q3 2015.
- Funds reported $218M of Rocket Pharmaceuticals stock for Q4 2015, up 24% quarter-over-quarter.
- 16 funds opened new Rocket Pharmaceuticals positions in Q4 2015 and 8 closed out, a net change of +8 holders.
- The largest Rocket Pharmaceuticals buyer in Q4 2015 was BlackRock Fund Advisors, an estimated $3.38M added.
- The largest Rocket Pharmaceuticals seller in Q4 2015 was Rho Capital Partners, an estimated $2.65M sold.
Based on aggregated 13F filings for Q4 2015.